Select therapeutic use:
Indications for ORFADIN ORAL SUSPENSION:
Treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Adults and Children:
Caps: take ≥1hr before or 2hrs after a meal. May open and mix contents in water, formula, or applesauce if difficulty swallowing caps or intolerant to oral susp. Initially 0.5mg/kg twice daily. Titrate individually as needed based on response. Monitor plasma and/or urine succinylacetone levels, liver function, and alpha-fetoprotein levels. Increase to 0.75mg/kg twice daily if succinylacetone is still detectable 1 month after treatment initiation; max 2mg/kg total daily dose may be needed. Maintenance: ≥5yrs with undetectable succinylacetone levels after a minimum of 4wks therapy on a stable dose: may give total daily dose once daily (eg, 1–2mg/kg once daily).
Maintain dietary restriction of tyrosine and phenylalanine during therapy. Do not adjust dose to lower plasma tyrosine levels (maintain levels at <500μmol/L). Perform eye exams (including slit-lamp test) prior to starting therapy; re-evaluate and assess plasma tyrosine levels if ocular symptoms develop. Perform lab tests (including plasma tyrosine levels) if abrupt change in neurologic status occurs. Monitor platelets, WBC counts during therapy. Oral susp: glycerol content (>20mL as a single-dose) may increase risk of adverse effects (eg, headache, upset stomach, diarrhea). Elderly. Pregnancy. Nursing mothers.
May potentiate CYP2C9 substrates; monitor.
4-hydroxyphenylpyruvate dioxygenase inhibitor.
Elevated tyrosine levels, thrombocytopenia, leukopenia, conjunctivitis, corneal opacity, keratitis, photophobia, eye pain, blepharitis, cataracts, granulocytopenia, epistaxis, pruritus, exfoliative dermatitis, dry skin, maculopapular rash, alopecia.
Caps—60; Oral susp—90mL